EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients

DSpace/Manakin Repository

EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients
 
Thijs, Judith L.; Drylewicz, Julia; Fiechter, Renée; Strickland, Ian; Sleeman, Matthew A.; Herath, Athula; May, Richard D.; Bruijnzeel-Koomen, Catharina A.F.M.; Knol, Edward F.; Giovannone, Barbara; de Bruin-Weller, Marjolein S.; Nierkens, Stefan; Hijnen, Dirk Jan
(2017) Journal of Allergy and Clinical Immunology, volume 140, issue 6, pp. 1703 - 1705
(Comment)
Download/Full Text
The full text of this publication is not available.
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: Immunology and Allergy, Immunology, Letter, Research Support, Non-U.S. Gov't
DOI: https://doi.org/10.1016/j.jaci.2017.06.046
ISSN: 0091-6749
Publisher: Mosby Inc.
Note: Funding Information: The study was supported in part by MedImmune. Funding Information: Disclosure of potential conflict of interest: I. Strickland and A. Herath are former employees of MedImmune. M. A. Sleeman was employed by MedImmune Ltd at the time of this study and previously held shares in AstraZeneca. R. D. May is employed by MedImmune and receives stock/stock options as part of his compensation. C. A. F. M. Bruijnzeel-Koomen has received grants from MedImmune and UMC Urtrecht (grant no. CW435174). M. S. de Bruin-Weller has board memberships with Regeneron/Sanofi and AbbVie, has consultant arrangements with Regeneron/Sanofi, and has received grants from Regeneron/Sanofi. D. J. Hijnen has received grants from MedImmune and UMC Urtrecht (grant no. CW435174) and Regeneron and is on advisory boards for MedImmune and Novartis. The rest of the authors declare that they have no relevant conflicts of interest.
(Peer reviewed)